SCHEMBL6731982

SCHEMBL6731982

N#Cc1cc(F)c(Oc2cccc(NCc3cccnc3)c2)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 1/20 0.50
PABPC1 P11940 1/20 0.50
CYP19A1 P11511 3/20 0.48
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPK14 Q16539 2/20 0.46
LTA4H P09960 1/20 0.44
MAP3K8 P41279 2/20 0.44
CYP3A4 P08684 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
MAPK13 O15264 1/20 0.41
EIF2AK2 P19525 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736390 0.86 MEN1 (0.50) MEN1KMT2AMAPTPABPC1CYP19A1
SCHEMBL6733124 0.82 MAPT (0.59) MEN1KMT2AMAPTPABPC1ALDH1A1
SCHEMBL6732917 0.76 LTA4H (0.56) MEN1KMT2AMAPTPABPC1ALDH1A1
SCHEMBL6731979 0.76 LTA4H (0.56) MEN1KMT2AMAPTPABPC1ALDH1A1
SCHEMBL6735252 0.75 MEN1 (0.52) MEN1KMT2AMAPTPABPC1CYP19A1
SCHEMBL6735876 0.75 MAPK14 (0.68) MEN1KMT2AMAPTCYP19A1ALDH1A1
SCHEMBL6732732 0.74 LTA4H (0.57) MEN1KMT2AMAPTPABPC1ALDH1A1
SCHEMBL6731984 0.74 ALDH1A1 (0.50) CYP19A1ALDH1A1SMN1; SMN2MAP3K8TDP1
SCHEMBL19312422 0.72 LTA4H (0.60) MEN1KMT2AMAPTPABPC1ALDH1A1
SCHEMBL6732463 0.72 CYP2C19 (0.62) MEN1KMT2AMAPTPABPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US disclosed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 MEN1 2793/4885KMT2A 3440/4885MAPT 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.